why choose us

First received: December 13, 2022

Clinical Trial: Phase 1 Study of OLX-07010 in Healthy Adult and Elderly Participants

Study Status: ACTIVE_NOT_RECRUITING

Recruit Status: ACTIVE_NOT_RECRUITING

Condition: Alzheimer Disease

Study Type: INTERVENTIONAL


Official Title: Phase 1 Randomized, Double-Blind, Single Ascending Dose, Multiple Ascending Dose, and Food Effect Study of the Safety, Tolerability, and Pharmacokinetics of OLX-07010 in Healthy Adult and Elderly Part

Brief Summary: This First-in-human (FIH) study will evaluate the safety, tolerability, and pharmacokinetics of the tau self-association inhibitor, OLX-07010 in single ascending doses (SAD) and multiple ascending doses (MAD) in healthy adults (18-50 of age inclusive), and single dose in healthy elderly (51-75 of age inclusive).The effects of dosing with or without food in healthy adults will also be studied (optional).

Read more